A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of the study is to determine the highest dose of TPI-287 that is safe and tolerable when administered as an intravenous infusion to participants with mild to moderate Alzheimer's disease (AD), to measure pharmacokinetic properties of the drug as well as to gauge preliminary efficacy of TPI-287 on disease progression.

Key facts

Study ID

NCT01966666

Run by

University of California, San Francisco

People needed

29

Starts

2013-11-01

Expected to finish

2019-09-01

Last updated by the study team

2020-04-14

Who can join

Age: 50 and older, up to 82. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Memory and Aging Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.